Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Volcano Cuts Deeper Into Peripheral Market With AtheroMed Buy

This article was originally published in The Gray Sheet

Executive Summary

Volcano will pay $115 million, plus a potential milestone, for AtheroMed and its Phoenix atherectomy system, as part of the firm’s growing emphasis on the peripheral artery device market.

You may also be interested in...



As Device Firms Take Costa Rica By Storm, Quality Control Experts Champion 'Pura Vida'

"Pura Vida" – a Spanish phrase meaning the "pure" or "simple life" – isn't just the unofficial motto of Costa Rica; rather, it's a state of mind, locals say. But as more and more medical device manufacturing facilities pop up in the tiny Central American nation, quality assurance professionals there have discovered that ensuring top-notch product quality doesn't necessarily make life simpler. To jump that hurdle, QA experts from a variety of firms – including Medtronic, Precision Concepts and Creganna Medical – have banded together to lean on each other as they search for solutions to quality systems issues, as well as knowledgeable input on hot quality and compliance topics.

Philips Increases Bet On Imaged-Guided Therapy With Volcano Buy

The imaging giant's $1.2 billion acquisition of intravascular assessment specialist Volcano deepens Philips' play in hospital cath labs and, Philips' CEO says in an interview, provides a combination of technology and know-how to create new catheter-based therapies for high-growth disease markets.

Device/Diagnostics Quarterly Deal Statistics, Q2 2014

Device funding increased 123% to $1.6 billion in Q2, and M&A activity was overshadowed by Medtronic’s massive $47 billion acquisition of Covidien. Diagnostics fundraising dropped slightly to $522 million, and there were multiple takeovers of life sciences companies.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT033035

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel